CalciMedica Regains Nasdaq Compliance After Reverse Split
CALC is trading near its 52-week low of $1.87 (5.9% above the low) on light trading volume (0.1× avg).
Summary
CalciMedica regained compliance with Nasdaq's minimum bid price rule after its reverse split, eliminating the delisting threat.
Key Events · Legal and Risk Events · CALC
-
Nasdaq Compliance Regained
Nasdaq Staff confirmed on September 15, 2026 that CalciMedica's closing bid price was at or above $1.00 for 10 consecutive business days (August 31 – September 14, 2026), satisfying Listing Rule 5550(a)(2).
-
No Outstanding Deficiency Notices
As of the filing date, the company has no outstanding deficiency notices from Nasdaq, clearing the delisting risk that had been pending since the March 16, 2026 notice.
-
Reverse Split Enabled Compliance
The compliance follows the 1-for-5 reverse split executed on August 31, 2026, which lifted the share price above the $1.00 threshold.
-
Going Concern Risk Remains
The company's Q2 2026 10-Q disclosed a going concern warning with only $18.6 million in cash, funding operations into the second half of 2027; the listing compliance does not address this underlying financial pressure.
Analysis · CALC · Life Sciences
CalciMedica has officially cleared its Nasdaq minimum bid price deficiency. The Staff confirmed the stock traded at or above $1.00 for 10 consecutive business days following the August 31 reverse split, and the company now has no outstanding deficiency notices. This removes a near-term delisting overhang that had been hanging over the stock since March, though the company's going-concern warning and cash runway pressures remain unchanged.
How filings like this one have moved
In the 30 days to Oct 29, 2026, 30.9% of the 1649 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.02%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, CALC was trading at $1.98 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $13.5M. The 52-week trading range was $1.87 to $36.00. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.